Table 1.
Clinical characteristics of patients with CD and UC
| Clinical feature | CD-act | CD-rem | UC-act | UC-rem |
|---|---|---|---|---|
| State | Active | Clinical remission | Active | Clinical remission |
| Number of subjects | 17 | 17 | 7 | 7 |
| Age, years | 14.9 ± 2.6 | – | 15.3 ± 2.4 | – |
| Disease duration between start and endpoint, months | – | 17.0 ± 9.3 | – | 8.07 ± 8.74 |
| Sex, M:F | 9:8 | 9:8 | 6:1 | 6:1 |
| PCDAI | 37.1 ± 15.9 | 3.8 ± 4.5 | – | – |
| PUCAI | – | – | 35.7 ± 23.7 | 1.4 ± 2.4 |
| Calprotectin, mg/kg | 830.8 ± 534.7 | 569.8 ± 764.9 | 655.2 ± 148.3 | 251.5 ± 291.5 |
| SES-CD | 13.53 ± 7.8 | 6.4 ± 5.1 | – | – |
| UCEIS | – | – | 4.3 ± 1.8 | 0.5 ± 0.7 |
| Disease location, n (%) | – | – | – | – |
| Ileal | 1 (6) | – | – | – |
| Colonic | 6 (35) | – | – | – |
| Ileocolonic | 10 (59) | – | – | – |
| Fistula, n (%) | 10 (59) | 2 (12) | – | – |
| Disease extent, n (%) | – | – | – | – |
| Left-sided | – | – | 6 (86) | – |
| Pancolonic | – | – | 1 (14) | – |
| Treatment prior to collection, n (%) | – | – | – | – |
| Anti-tumor necrosis factor alpha | – | 12 (71) | – | 5 (71) |
| Exclusive enteral nutrition | – | 3 (18) | – | – |
| Corticosteroids | 1 | 4 (23) | 2 | 2 (29) |
| Azathioprine | 2 | 9 (53) | 2 | 5 (71) |
| 5-Aminosalicylic acid | – | – | 1 | 3 (43) |
| None | 14 (82) | – | 3 (43) | – |
| Surgery, n (%) | – | 2 (12) | – | 0 |
| Seton operation | – | 1 | – | – |
| Hemicolectomy | – | 1 | – | – |
| Mucosal remission, n (%) | – | 6 (35) | – | 5 (71) |
CD, Crohn disease; PCDAI, Pediatric Crohn’s Disease Activity Index; PUCAI, Pediatric Ulcerative Colitis Activity Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease; UC, ulcerative colitis; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.